High levels of centrosomal protein 55 expression is associated with poor clinical prognosis in patients with cervical cancer.

Centrosomal protein 55 (CEP55) has been proposed to have a role in tumor development. However, the expression pattern and clinical relevance of CEP55 has, to the best of our knowledge, not yet been investigated in cervical cancer. The mRNA levels of CEP55 in cervical cancer tissues and paired adjacent non-cancerous tissues were examined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The present study assessed the association between immunohistochemical staining of CEP55 and clinicopathological characteristics and survival rates of patients. Compared with the adjacent non-cancerous tissues, CEP55 expression was significantly increased in cervical tumor tissues, as demonstrated by the results of RT-qPCR. High expression of CEP55 was significantly associated with lymph node metastasis (P=0.008) and advanced tumor stage (P=0.010). Furthermore, CEP55 overexpression in cervical cancer specimens was significantly associated with poor 5-year overall and recurrence-free survival rates (P=0.021 and P=0.010, respectively). The results of multivariate Cox regression analysis revealed that CEP55 expression was a significant, independent predictor for the survival of patients with cervical cancer (hazard ratio=3.057; P=0.035). These data indicated that high CEP55 expression was associated with lymph node metastasis and was an independent predictive factor for an unfavorable prognosis in patients with cervical carcinoma.